The KEYNOTE-o42 trial demonstrated that taking Keytruda was more effective in treating lung cancer than chemotherapy, and further findings could mean that patients can skip chemo treatment altogether. The recent stock gain represents almost $5.75 billion in market value.
Keytruda earned Merck more than $3.8 billion in sales in 2017.
More articles on business:
Boeing swipes $12B American Airlines order from rival Airbus
Viacom asks CBS to increase merger offer by $2.8B
Facebook suspends 2 more analytics companies in wake of scandal
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
